GLP-1 medications have become the most-studied weight loss drugs in modern medicine. Between large-scale clinical trials and growing real-world data, we now have a solid picture of what these medications actually deliver — and where the limits are. The numbers are impressive, but they also tell a more nuanced story than the headlines suggest.
Semaglutide: The STEP Trials
The STEP trial program is the foundation of everything we know about semaglutide for weight loss. STEP 1, the landmark study, enrolled over 1,900 adults with obesity. Participants on semaglutide 2.4 mg (the Wegovy dose) lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. For a 250-pound person, that's roughly 37 pounds.
STEP 2 focused on patients with both type 2 diabetes and obesity — a tougher population to treat. Weight loss averaged 9.6%, lower than STEP 1 but still substantial. The pattern held across STEP 3 through 5: consistent weight loss in the 10-17% range depending on the population and whether behavioral interventions were included.
The newest data comes from the STEP UP trial, which tested a higher 7.2 mg dose. Average weight loss hit 20.7% — roughly one in three participants lost 25% or more of their body weight. The FDA approved this higher dose (Wegovy HD) in early 2026.
Tirzepatide: The SURMOUNT Results
Tirzepatide works on two receptors (GLP-1 and GIP) instead of one, and the clinical results reflect that dual action. SURMOUNT-1, the flagship trial, showed average weight loss of 20.9% at the highest dose (15 mg) over 72 weeks. That's roughly 52 pounds for someone starting at 250. About one-third of participants on the top dose lost 25% or more of their starting weight.
SURMOUNT-2, which studied patients with diabetes, showed 12.8% weight loss at the 15 mg dose. Again, less than the non-diabetes population, but strong by any historical standard. These results are why tirzepatide (sold as Zepbound for weight loss) has generated so much interest.
Real-World Results vs Clinical Trials
Clinical trials use carefully selected patients, regular check-ins, and structured protocols. Real-world outcomes are typically more modest. Early observational data suggests that average weight loss outside of trials runs about 10-15% of body weight for semaglutide and 12-18% for tirzepatide. Still meaningful, but worth calibrating your expectations.
Adherence is the biggest factor. People who stick with the medication, follow up with their provider, and make dietary adjustments tend to land closer to the trial numbers. People who miss doses, don't adjust their eating habits, or stop treatment early see less benefit. If you hit a stall, our guide on breaking through GLP-1 plateaus covers practical strategies.
How Long Does It Take?
Most patients notice appetite changes within the first week or two. Visible weight loss typically starts around weeks 4-8, depending on the dose titration schedule. The steepest weight loss usually happens between months 3 and 9. After that, the rate slows and most people reach a plateau around 12-15 months. This isn't a failure — it's how the medications work. Your body settles at a new, lower set point.
The Weight Regain Question
The STEP 1 extension trial showed that participants who stopped semaglutide after 68 weeks regained about two-thirds of their lost weight within a year. This is the uncomfortable truth: for most people, GLP-1 medications work best as a long-term treatment, not a short course. The underlying biology of obesity doesn't change just because you've lost weight. Ongoing treatment, whether with medication or intensive lifestyle changes, matters for keeping it off. The Obesity Society maintains a comprehensive research library on long-term weight management outcomes for those who want to dig deeper into the clinical data.
If you're ready to get started, find a GLP-1 provider near you and discuss what realistic results look like based on your specific health profile and goals.